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ABSTRACT
Sequencing technologies and new bioinformatics
tools have led to the complete sequencing of
various genomes. However, information regarding
the human transcriptome and its annotation is yet
to be completed. The Human Cancer Genome
Project, using ORESTES (open reading frame EST
sequences) methodology, contributed to this
objective by generating data from about 1.2 million
expressed sequence tags. Approximately 30% of
these sequences did not align to ESTs in the
public databases and were considered no-match
ORESTES. On the basis that a set of these ESTs
could represent new transcripts, we constructed a
cDNA microarray. This platform was used to hybri-
dize against 12 different normal or tumor tissues.
We identified 3421 transcribed regions not asso-
ciated with annotated transcripts, representing
83.3% of the platform. The total number of differen-
tially expressed sequences was 1007. Also, 28% of
analyzed sequences could represent noncoding
RNAs. Our data reinforces the knowledge of the
human genome being pervasively transcribed, and
point out molecular marker candidates for different
cancers. To reinforce our data, we confirmed, by
real-time PCR, the differential expression of three
out of eight potentially tumor markers in prostate
tissues. Lists of 1007 differentially expressed
sequences, and the 291 potentially noncoding
tumor markers were provided.
INTRODUCTION
Understanding the genetic basis of human development
and the mechanisms implicated in the physiopathology
of diseases has improved dramatically after the disclosure
of the human genome sequence, and its encoded genes
(1–3). It is now widely accepted that, in mammals, there
is no linear correlation between the number of genes, tran-
scripts, and functionally diverse proteins. In the human
transcriptome, a myriad of controlling mechanisms invol-
ving alternative splicing and a diversity of 50 and 30 ends
contribute to, a yet unknown universe of transcripts (4).
It is known that most of the genome is transcribed in
complex patterns of interacting and overlapping tran-
scripts from both strands (5–9), and most mammalian
genes also have antisense transcripts (7,9–11). We cur-
rently have a great deal of information (4,5,12–14) arising
from modern technologies, such as tiling arrays, that con-
ﬁrm the genome to be pervasively transcribed, and that
the noncoding regions, such as the introns and intergenic
regions, play an important role in human genome regula-
tion by cis-acting at the transcriptional level (4,15,16).
These approaches have resulted in the discovery of many
novel transcribed sequences, and provide a new perspec-
tive on the number and extent of transcripts.
Noncoding RNAs (ncRNAs) are emerging as key
players in transcriptional and translational control, and
represent a new level of complexity (17,18). Available
data shows that the ratio of noncoding versus coding
RNAs increases from prokaryotes to mammals (6,19).
Furthermore, ncRNAs appear to have cell- or condition-
restricted expression, and at lower levels compared with
the well-characterized coding genes (20–22). In addition,
although cross-species conservation of many ncRNA tran-
scribed regions is weak, promoters of these transcripts are
generally much more evolutionarily conserved, and the
conserved regions extend further than in the promoters
of protein coding RNAs (5kb versus 500bp) (5,22,23).
In recent years, the use of bioinformatics tools allied to
experimental studies, particularly for the whole genome,
has become a common and promising means to predict
and screen novel ncRNAs and antisense RNAs
(10,14,22,24,25).
Although sequencing eﬀorts based on generating cDNA
fragments had a major impact on gene discovery, the
unspliced human transcripts that map exclusively to
introns, and with no similarity to known expressed
genes from any organism, were not fully appreciated.
*To whom correspondence should be addressed. Tel: +55-11-2189-5000-1134; Fax: +55-11-2189-5163; Email: helena@lbhc.hcancer.org.br.
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Most investigators selected transcripts with evidence of
splicing, or ESTs only where both a polyadenylation
signal and a poly(A) tail were present (18). It is now
accepted that only a small fraction of the sequences gen-
erated through EST methods represent mitochondrial
transcripts, reverse transcribed copies of rRNA, bacterial
contaminants or immature mRNA molecules (26,27).
Large fractions of what were, until recently, considered
‘junk’ DNA are indeed transcribed, and may play a fun-
damental role in understanding genomes (5,15,28). In
addition, the results presented by Ravasi et al. (29) show
that most of the cloned, noncoding sequences in the
RIKEN cDNA collection, are expressed and are not, on
the whole, derived from genomic, or pre-mRNA (prema-
ture mRNA), contamination.
A large contribution toward identifying ESTs was the
Human Cancer Genome Project (HCGP) (3,26,27,30),
performed by the ORESTES (open reading frame EST
sequences) methodology. ORESTES is a technique to gen-
erate ESTs encompassing midpoints of genes, unlike con-
ventional EST methodologies (50 and 30) that cover
the ends of transcripts. This characteristic results from
the cDNA synthesis using arbitrarily selected, nondegene-
rate primers under low-stringency conditions, that permits
sequence analysis of less abundant gene transcripts, and
therefore, lead us to access genes with lower levels of
expression (26). Thus, the HCGP, through ORESTES
methodology, generated 1190044 open reading frame
EST sequences using RNA extracts from 24 types of
normal or tumor tissues (3,27). From this total, almost
30% (341680 sequences) showed no similarity with
known transcripts and were considered no-match
ORESTES (27). With the aim to explore the potential of
ORESTES with no similarities with ESTs in the public
databases as tumor markers, we constructed a cDNA
microarray. This platform, containing ORESTES with a
high probability of representing actively transcribed
regions not associated with annotated transcripts, was
hybridized against 12 diﬀerent normal and tumor human
tissues. The diﬀerential expression observed among
distinct tissues or pathological conditions demonstrates
that this strategy was very useful for identifying tissue-
speciﬁc, or tumor-speciﬁc RNAs that do not correspond
to previously annotated transcripts. These hitherto-
uncharacterized transcripts may represent new human
genes, splice variants, ncRNAs or natural antisense tran-
scripts (NATs) with a restricted pattern of gene expres-
sion. As prostate tumor is the most prevalent cancer in
the Brazilian male population (http://www.inca.gov.br),
we have explored some of these sequences as potential
prostate tumor markers.
MATERIALS AND METHODS
Selection of ORESTES andgenome mapping
To construct the array, 4356 ORESTES with higher prob-
ability to represent actively transcribed regions of the
human genome not associated with annotated transcripts,
were randomly selected from the data generated by
Fonseca et al. (31), resulted from the exploration of the
341680 ORESTES from the Human Cancer Genome
Project that showed no similarity to known transcripts
(27). In this work, a bioinformatics pipeline was con-
structed for the sequences mapped on the human
genome that were annotated as no-match in the Human
Cancer Genome Project, starting with the removal of
sequences derived from libraries containing genomic
DNA or immature mRNA contamination, according to
Sorek & Safer, 2003 (32), followed by selection of clusters
containing at least one no-match sequence derived from
prostate or breast tissues and that were formed by ESTs
originating from at least two distinct libraries, and the
singletons that showed gaps upon genomic alignment.
Also, clusters aligned with full-length transcripts or
ESTs of other projects were removed.
Genome mapping was done through a local data-
base composed of data downloaded from the UCSC
Genome Bioinformatics database (http://genome.ucsc.
edu). ORESTES were classiﬁed according to their map-
ping on the human genome using three diﬀerent gene
tracks (Ensembl, KnownGene and RefSeq), and
sequences mapped once on the genome were further clas-
siﬁed as exonic, intronic and intergenic sequences.
cDNA microarrays
Glass arrays with 4356 elements were prepared in our lab
with the aid of the Flexys Robot (Genomic Solutions, Ann
Arbor, MI, USA), as described by Brentani et al., 2005
(33). Microarray data are deposited at Gene Expression
Omnibus (GEO) under accession number GSE12737.
Detailed information is provided in Supplementary Data.
RNA extraction and amplification
The institutional research ethics committee approved the
current study (REC number 970/07), which was per-
formed in accordance with the principles expressed in
the Declaration of Helsinki. All samples kept in the
A.C. Camargo Hospital BioBank, have signed informed
consent for use in research, provided and approved by
patients.
Total RNA derived from 56 normal or tumor tissues,
obtained from the A.C. Camargo Hospital BioBank, was
extracted with TRIzol (Invitrogen, Carlsbad, CA, USA)
(Supplementary Data, Table S1). As a reference, we used a
pool of RNAs obtained from 15 distinct human cell lines
(Table S2). RNA samples were linearly ampliﬁed using a
T7-based protocol (34,35). cDNA was prepared with ami-
noallyl-dUTP (Sigma–Aldrich, St. Louis, MO, USA) (36).
Detailed information is provided in Supplementary Data.
Labeling, hybridization and dataextraction
cDNA samples were submitted to indirect labeling (36)
using Alexa Fluor 555 or Alexa Fluor 647 labels
(Invitrogen). Hybridizations were performed in duplicate
using the dye-swap method (35,37) in the GeneTAC
Hybridization Station (Genomic Solutions). Slides were
scanned on a confocal laser scanner (ScannArray
Express, PerkinElmer, Waltham, MA, USA), using
identical parameters for all slides and data was extracted
with ScanArray Express software (PerkinElmer).
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local background intensities. Detailed information is pro-
vided in Supplementary Data.
Selection ofbonafide transcripts
After subtracting local background, data was normalized
by Lowess (38). For each sample, we determined the cor-
relation between replica hybridizations and the number of
spots with signal greater than local background. We also
determined, for each sample, the diﬀerences between aver-
age signal intensity for elements representing intergenic or
intragenic (exonic and intronic) sequences and for exonic
or intronic sequences. To deﬁne a sequence as expressed,
and to minimize the risk of a false-positive call, we applied
a second level of cutoﬀ for low-intensity spots. First, we
determined, for each element, the lowest background-
corrected intensity value among the 112 reads (main and
swap slides) in each channel. Then, for each channel,
we considered, as threshold, the highest value among the
112 lowest reads in each slide. Next, we eliminated, for
each channel, all elements with median intensity below
this threshold. Elements that survived these criteria were
considered bonaﬁde transcripts. For all expression data we
applied log2 to the values.
Prediction of structured ncRNA candidates
Genomic sequences corresponding to ORESTES were
analyzed to predict structured ncRNAs candidates.
First, we separated the sequences into three groups: fully
exonic, partially exonic, and nonexonic, according to the
annotation systems KnownGene and RefSeq (UCSC
Genome Bioinformatics). For each group, we combined
searches for three features: (i) putative ORF, (ii) coding/
noncoding potential of sequences and (iii) sequence
and secondary structure conservation. To determine if a
sequence is entirely an ORF, we used the getorf program
(EMBOSS program suite, http://www.ebi.ac.uk/Tools/
emboss), which analyzes if the three reading frames of
both strands of the sequence could generate a coding
sequence, and checked if the longest ORF identiﬁed by
this software corresponded to the whole sequence (or its
trimmed version of up to 2 bases from each end). Also, we
used the Coding Potential Calculator (CPC) software (39),
with default parameters, which classiﬁes sequences in
coding and noncoding (weak-coding, coding, weak
noncoding and noncoding), to reﬁne our initial ORF pre-
diction. This software takes into account six features,
being three of them based on the predicted ORF exten-
sion, quality and integrity, and the other three derived
from BLASTX searches (UniRef90, BLAST Assembled
Genomes; http://blast.ncbi.nlm.nih.gov/Blast.cgi): the
number, quality and frame of the hits. We grouped
sequences classiﬁed as noncoding or weak noncoding
and sequences classiﬁed as coding and weak coding.
To detect sequence and secondary structure conservation,
we searched for multispecies alignments (16 vertebrate
genomes with human http://hgdownload.cse.ucsc.edu/
goldenPath/hg18/multiz17way) that overlapped the
ORESTES sequence locations. These alignments were
analyzed using the RNAz software (40) with default
parameters, to detect evidence of secondary structure
conservation, like compensatory base substitution.
Validation by RT-PCR
To select sequences for validation by RT-PCR, we ﬁrst
determined the average intensity value for each element
in all slides. Using an MA plot (intensity ratios versus
average intensities), we randomly selected elements with
intensity 20-fold higher than the background (cutoﬀ
value of log212 for A, average intensities), since we
intended to validate highly expressed sequences. Primers
for 12 selected sequences were designed using Primer3
software (http://frodo.wi.mit.edu) (Table S3). RNAs
from 23 normal or tumor tissues were obtained from the
A.C. Camargo Hospital BioBank (Table S1), extracted
with TRIzol (Invitrogen) and DNase treated (Illustra
RNAspin Mini Isolation Kit, GE Healthcare,
Buckinghamshire, ENG, UK). RT-PCR reactions were
carried on Gene Amp PCR System 9700 (Applied
Biosystems, Foster City, CA, USA) and the amplicons
were fractionated by electrophoresis thorough a 3%
NuSieve GTG (Cambrex, East Rutherford, NJ, USA)
and stained with ethidium bromide. Detailed information
is provided in Supplementary Data.
Differential expression analysis
To select diﬀerentially expressed sequences to be consid-
ered as tumor marker candidates we constructed MA plots
showing, for each spot, fold diﬀerences and median signal
intensity for tumor versus normal tissues. For these ana-
lyses, three (placenta, lung and testis) out of 12 tissues
that were used in cDNA microarray experiments were
discarded because we had only normal samples from
them, and therefore, we could not perform diﬀerential
expression analyses with the aim to identify tumor mar-
kers for these tissues.
Validation by quantitative real-time PCR
To select sequences to validate by real-time PCR, we
determined, for each element, fold diﬀerences between
median signal intensity for: (i) prostate tumor versus
normal prostate tissue and (ii) prostate tumor versus
all normal tissues analyzed on cDNA microarray experi-
ments. Using MA plots, we selected elements expressed at
least 4-fold more or 4-fold less in prostate tumor relative
to normal prostate, and at least 2-fold more or 2-fold less
in prostate tumor relative to all normal tissues (values
converted to log2). Primers were constructed for nine
sequences diﬀerentially expressed in prostate tissue,
using Primer Express software (Applied Biosystems) and
Oligo Tech program (http://www.oligosetc.com/analy
sis.php) (Table S5). Real-time PCR reactions were
optimized using a pool of RNAs from three tumor pros-
tate cell lines (PC-3, DU 145 and LNCaP), provided
by the Sa ˜ o Paulo branch of the Ludwig Institute for
Cancer Research, and cultivated by the Laborato ´ rio
de Investigac ¸ a ˜ oM e ´ dica/24 from Universidade de Sa ˜ o
Paulo. Real-time PCR validation was performed in
seven paired samples from prostate (prostate adenocarci-
noma and its surrounding non-neoplasic tissue), obtained
Nucleic Acids Research,2009, Vol.37, No. 8 2609from the A.C. Camargo Hospital BioBank (Table S6),
extracted with TRIzol (Invitrogen) and DNase treated
(RQ1 RNase-Free DNase, Promega, Madison, WI,
USA). Real-time PCR experiments were carried out in
duplicate using the SYBR Green detection method
(Applied Biosystems). The housekeeping gene HPRT
was selected through literature review (41). We used a
previously described molecular marker for prostate
carcinoma (AMACR) (42) as positive control for real-
time PCR reactions. Real-time PCR was performed on a
7900HT Fast Real-Time PCR System (Applied
Biosystems). The relative expression ratio was calculated
according to Pfaﬄ formula (43). For all expression data
we applied log2 to the values. Detailed information is
provided in Supplementary Data.
Sequencingof validated ORESTES
ORESTES validated as real-transcripts by RT-PCR had
their PCR products sequenced to verify their correspon-
dence to the immobilized sequences and diﬀerentially
expressed ORESTES validated by real-time PCR had
their original clones sequenced to verify their correspon-
dence to the sequences with which we expected that they
were. Sequencing was carried on the 3130 Genetic
Analyzer (Applied Biosystems). Detailed information is
provided in Supplementary Data.
RESULTS
Genomic mappingof thecDNA microarraysequences
An analysis comparing the genomic location of ORESTES
and non-ORESTES ESTs, with respect to coordinates of
coding genes, was performed. As expected, we found
that both non-ORESTES ESTs, as well as ORESTES,
were preferentially mapped in transcribed regions of
the human genome, using three diﬀerent gene tracks
(RefSeq, Ensembl and KnownGene, UCSC Genome
Bioinformatics; http://genome.ucsc.edu) (Figure 1A).
The proportion of ORESTES sequences that overlapped
annotated exons of coding genes was somewhat reduced in
the ORESTES data set (Figure 1B). The preferential map-
ping of ORESTES to transcriptional units suggests that
fully intronic ORESTES may represent valid transcripts
instead of genomic DNA contamination of ORESTES
libraries.
We constructed a cDNA microarray containing 4356
distinct ORESTES, selected using a previously described
pipeline developed to maximize the probability of identi-
fying new expressed sequences (31). Our data showed that
most ORESTES that compounded the array was mapped
to transcribed regions of the genome (Figure 1A), and had
a fully intronic location (Figure 1B). Only a small fraction
of spotted sequence overlapped annotated exons of coding
genes or had intergenic mapping (Figure 1). For further
analysis, we considered 3872 sequences that map once
to the human genome. We divided these sequences into
exonic (335 sequences), intronic (3178 sequences) and
intergenic sequences (359 sequences), representing 8.6%,
82.1% and 9.3% of the sequences respectively. A large
proportion of these ORESTES (3767) are unspliced rela-
tive to the genome.
Analysis and identification of actively transcribed regions
not associated withannotatedtranscripts, and their
evaluation as potential ncRNAs
Many low expression transcripts, splicing isoforms and
ncRNAs are involved in specialized biological functions,
and show a tissue-speciﬁc or even a pathological-speciﬁc
expression patterns. To survey new transcripts associated
with ORESTES, 24 tumor and 32 normal RNA samples
from 12 diﬀerent tissues (Table S1) were hybridized with
the microarray platform.
Some preliminary analyses were performed to determine
the overall quality of data. The Pearson correlation
between two replicate slides showed a median value of
0.86, and 76% of the elements that compounded this plat-
form had signal greater than local background. We inves-
tigated if there was any bias that could be associated with
the diﬀerent types of sequences immobilized on the array,
according to the previous classiﬁcation: exonic, intronic or
intergenic sequences. Using the Wilcoxon test, there were
no statistically signiﬁcant diﬀerences in either case, i.e. in
the comparison of average signal intensity for elements
representing intergenic or intragenic sequences, as well
as in the comparison of only intragenic (exonic or intro-
nic) sequences. The spotted sequences showed no system-
atic bias associated with their classiﬁcation, corroborating
Figure 1. Mapping of ESTs on the human genome according to three diﬀerent data sets. (A) ESTs mapped onto human transcript regions. (B) ESTs
mapped onto human exonic regions. Black bar, ESTs; gray bar, ORESTES (open reading frame expressed sequence tags); and white bar, ORESTES
that compound the cDNA microarray.
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regions as being transcribed sequences. To be more accu-
rate in deﬁning true hybridization signals we created a
more stringent criterion, described in ‘Materials and meth-
ods’ section, with signal intensity cutoﬀ values of 196 and
65 for channels 1 and 2, respectively. Thus, for each chan-
nel, we eliminated all elements with a median signal inten-
sity below these thresholds. For channels 1 and 2 we had
86.6% and 91.1% of slides with more than 3000 valid
elements, respectively. Therefore, the total number of
actively transcribed regions not associated with annotated
transcripts was 3421 (3079 out of 3178 intronic and 342
out of 359 intergenic sequences). The additional number
of 319 out of 335 exonic elements identiﬁed as valid ele-
ments, corroborated the potential of our approach to
identify new real, transcribed regions, since these
sequences were deposited by others in public databases
while this work was being performed. From this ﬁnal
number of valid elements (3740), 96 sequences (80 intro-
nic, 6 intergenic and 10 exonic sequences) had intensity
above our established cutoﬀ value (20-fold higher than
the background) and were eligible for RT-PCR validation.
From this 96 sequences, we arbitrarily selected nine intro-
nic sequences (roughly 11% of the total of intronic
sequences), and three intergenic sequences (50% of inter-
genic group) and validated the existence of all of them as
actively transcribed regions not associated with annotated
transcripts, in RNAs derived from 10 diﬀerent tissues
(Tables S1 and S3, Figure S1). PCR products of validated
sequences were submitted to sequencing and their corre-
spondence to the immobilized sequences on the array was
conﬁrmed.
Evidence of secondary structures coupled with some
sequence conservation at the RNA level can provide
important clues that a given ‘locus’ is probably tran-
scribed, and that this transcript may have a biological
role (14,40,44,45). RNA secondary structures are known
to play an important functional role, not only in many
noncoding transcripts, but also in the context of protein-
coding mRNAs (46). To analyze the proportion of spotted
sequences that may represent structurally conserved puta-
tive ncRNAs, we searched for three features: (i) putative
ORF, (ii) coding/noncoding potential and (iii) sequence
and secondary structure conservation. For this analysis,
sequences that did not overlap to known exons (intronic
and intergenic sequences) were grouped together (3537
sequences) and the exonic sequences were further classiﬁed
to fully exonic (131) and partially exonic (166). As for this
analysis we only considered the KnownGene and RefSeq
gene tracks to classify analyzed sequences, we discarded
38 sequences, previously classiﬁed as exonic according
to the initial mapping, using the RefSeq, Ensembl
and KnownGene gene tracks (UCSC Genome
Bioinformatics) (Figure S2). We considered as putative
ncRNAs sequences which presented all following features:
partially exonic or nonexonic mapping, CPC software
prediction of noncoding potential and evidence of
secondary structure conservation according to the
RNAz software. From the partially exonic sequences, we
found 38 putative ncRNAs and from the nonexonic
sequences, we found 1040 ncRNAs candidates (Table 1,
Figure S2). It is noteworthy that some known ncRNAs
possess a subsequence that is not as short as is usual, and
resembles an ORF (46). In summary, about 28% (1078 of
3834) of our transcribed regions, not associated with
annotated transcripts, are potential ncRNAs (Table 1,
Figure S2).
Differential expression analyses and validationby
quantitative real-time PCR
We constructed MA plots (intensity ratios versus average
intensities) showing, for each spot, fold diﬀerences and
median signal intensity for tumor versus normal tissues,
for all the diﬀerent tissues used in the cDNA microarray
(Figure 2). We observed in all tissues, a large number of
diﬀerentially expressed (at least 2-fold) sequences between
tumor and normal samples, suggesting the potential to
explore uncharacterized molecular markers (about 28%
of the intronic and intergenic sequences mapped once on
the genome). The total number of diﬀerentially expressed
sequences, with fold diﬀerences between tumor and
normal samples of at least two, in one or more diﬀerent
tissues and in agreement in respect to these sequences
being up- or downregulated in all tissues in which they
were expressed, were 1007, being 111 out of 335 exonic
sequences, 885 out of 3178 intronic sequences and 111 out
of 359 intergenic sequences (a list of all 1007 diﬀerentially
expressed sequences is provided in our website, http://
www.lbhc.hcancer.org.br/orestes_tumor_markers).
Considering the same criteria of diﬀerentially expressed
sequences described above, 291 transcripts were classiﬁed
as diﬀerentially expressed putative ncRNAs by our pipe-
line. Four percent of these putative noncoding tumor mar-
kers were in the NONCODE database (47), or were
Table 1. Putative noncoding RNAs and their distribution with respect to diﬀerential expression
Partially exonic sequences Nonexonic sequences
ORF+ ORF– ORF+ ORF–
Number of putative ncRNAs 0 38 58 982
Number of tissue types where putative ncRNAs
were diﬀerentially expressed
0 1 2 3 4 1 2 123 4 5
Number of upregulated putative ncRNAs 0 1 2 3 1 3 1 92 40 13 3 1
Number of downregulated putative ncRNAs 0 5 1 0 0 6 0 103 15 1 0 0
Number of putative noncoding tumor markers 0 13 10 268
ncRNAs (noncoding RNAs).
Nucleic Acids Research,2009, Vol.37, No. 8 2611predicted as an antisense pair by Galante et al. (48), again
corroborating the validity of our approach, but have never
been identiﬁed as diﬀerentially expressed in tumors.
In Table 1 we assessed whether these candidates were
expressed in one or more tumor tissues and found that
at least ﬁve putative noncoding tumor markers were upre-
gulated in at least four diﬀerent tumors (AW803984,
BE161676, CV358552, AW814925 and AW935941), com-
pared with normal tissues. This is a very promising result
for the search for tumor markers. A list of all putative
noncoding tumor markers is provided in Table S4.
We constructed MA plots to present an overview of the
sequence expression distribution in prostate tissue
(Figure 2A). For each spot, we observed the fold diﬀer-
ences and median signal intensity for prostate tumor
versus normal prostate (Figure 2A), and for prostate
tumor versus all normal tissues (Figure S3). The nine
sequences from prostate selected for validation by real-
time PCR (Table S5) had at least a 4-fold variation in
prostate tumor relative to normal prostate, and had at
least 2-fold variation in prostate tumor relative to all
normal tissues. We observed that, in general, the selected
sequences were diﬀerentially expressed only in prostate
when compared with other tissues (Figure 2, gray circles).
Using real-time PCR, we validated eight of the nine
sequences as real transcripts. We considered valid diﬀer-
entially expressed sequences as those that presented a
3-fold diﬀerence in at least three out of seven paired
samples. Using this criterion, three sequences were consid-
ered to be potential prostate tumor markers (Table 2).
One of the potential tumor markers (BQ373258) was pre-
viously described as a ncRNA (DD3
PCA3) by Bussemakers
et al. (49). Its diﬀerential expression was conﬁrmed in ﬁve
of our seven paired prostate samples, and was upregulated
in prostate cancer, serving as a positive control for
our real-time PCR experiments. The overexpression of
AW793062 ORESTES in prostate tumor was conﬁrmed
in four paired tissues. Genome mapping of this sequence
showed its alignment to the ﬁrst intron of a putative iso-
form of the RNF217 gene. The sequence BF910617 was
validated in three samples and showed overexpression in
prostate cancer. It is an intronic sequence of the
KIAA1432 gene. Considering our criteria of valid diﬀer-
entially expressed transcripts (3-fold diﬀerence in at least
three out of seven paired samples), we validated the over-
expression of the AMACR gene. This molecular marker
for prostate carcinoma was previously described as having
high sensitivity and speciﬁcity for prostate carcinoma
from diﬀerent grades and types, being its mRNA over-
expressed in about 30% (microarray) to 60% (real-time
PCR) of prostate tumors and is low to undetectable in
normal tissues (42,50,51).
A summary of all sequences and samples sets used
in each performed assay, as well as obtained results, is
provided in Supplementary Data (Table S7).
Figure 2. MA plot (intensity ratios versus average intensities) showing the fold diﬀerences and median signal intensity for tumor versus normal
tissues for each spot on microarray. (A) Prostate tissue. (B) Other tissues used on cDNA microarray. Gray circles, the sequences from prostate
selected for real-time PCR validation (with fold value in prostate tumor 4-fold more or 4-fold less relative to normal prostate and 2-fold more or
2-fold less, relative to all normal tissues). Dotted line, 2-fold line; dashed line, 4-fold line.
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Since a signiﬁcant set of ORESTES remains unassociated
with annotated transcripts, and could potentially repre-
sent actively transcribed regions of the human genome,
we constructed a cDNA microarray containing
ORESTES with a high probability of representing actively
transcribed regions of the human genome, and not asso-
ciated with annotated transcripts. Most of the sequences
immobilized on the array map on intronic regions and are
unspliced. After hybridization using 12 diﬀerent tissues,
we identiﬁed 3421 actively transcribed regions not
associated with annotated transcripts. With RT-PCR we
validated 100% of actively transcribed regions not asso-
ciated with annotated transcripts that were evaluated
(12 sequences).
Based on an ORF detector program (getorf, http://
www.ebi.ac.uk/Tools/emboss), only 9% of the sequences
mapped once on the genome may represent coding genes,
leading us to search for potential noncoding sequences.
In spite of the ORESTES methodology being biased to
cover transcript midpoints with high probability of repre-
senting open reading frames, our data showed that from
the sequences mapped to intronic or intergenic location
(nonexonic group) only 7.6% presented a putative ORF.
In contrast, 47.3% of fully exonic sequences had a puta-
tive ORF (Figure S2).
Our next step was to look for sequences that could be
tumor, tissue or tumor/tissue associated. We observed in
all tissues, a large number of diﬀerentially expressed
(at least 2-fold) sequences between tumor and normal
samples, suggesting the potential to explore uncharacter-
ized molecular markers (about 28% of the intronic and
intergenic sequences mapped once on the genome). The
total number of diﬀerentially expressed sequences, with
fold diﬀerences between tumor and normal samples of at
least two and in agreement in respect to these sequences
being up- or downregulated in all tissues in which they
were expressed, in one or more diﬀerent tissues, were
1007. We investigated the number of intronic ORESTES
that mapped in a cancer gene list, compounded by 382
genes for which mutations have been causally implicated
in cancer. This catalog of cancer genes is available on the
Sanger Institute (Cancer Gene Census, http://www.san-
ger.ac.uk/genetics/CGP/Census) and it is based on a pre-
viously published review (52). We found 189 intronic
ORESTES mapped to 97 cancer genes. The number
of the diﬀerentially expressed ORESTES, considering
the same criteria described above, located within introns
of these cancer genes were 47. Using a list of cellular signal
pathways curated by NCI-Nature (http://pid.nci.nih.gov),
we expanded the original list of cancer genes for 1003
cancer pathway related genes. We found that 287
ORESTES mapped to 170 cancer-pathway related genes.
From these 287 ORESTES related to cancer pathways,
70 were diﬀerentially expressed, considering the same
criteria described above.
De novo computational prediction of ncRNA genes is
diﬃcult, since these transcripts lack most of the signatures
that make protein-coding gene prediction possible (45).
However, ncRNA genes produce a functional RNA
rather than a translated protein, and often display a con-
served, base-paired secondary structure instead of primary
sequence similarity. These features can be combined in
analyses and result in proﬁles of a multiple sequence align-
ment of ncRNAs that can be captured by statistical
models (14,53). There are several approaches that are
used to successfully predict ncRNAs based on the idea
that functionally signiﬁcant RNA structures will be con-
served in related species, even when primary sequence is
not conserved (54). The secondary structure base pairings
are maintained by compensatory base mutations. These
changes can be used as statistical evidence of evolutionary
pressure to keep the base pairs at those positions
(14,40,44,45). Pedersen et al. (44) predicted, from an initial
set of more than 48 000 structured regions,  10 000 struc-
tured RNA transcripts in the human genome. Washietl
et al. (40) estimated that 35 000 structured RNAs are
conserved in mammals. The annotation of ncRNAs on a
genome-wide scale is currently restricted to searching
for homologs of known RNA families. More than
1500 homologs of known classical RNA genes can be
annotated in the human genome sequence, and automatic,
homology-based methods predict up to 5000 related
sequences (45). Major databases containing thousands of
annotated ncRNA sequences are RNAdb (10) and
Table 2. Results of quantitative real-time PCR validating paired prostate samples with cDNA microarray results
Accession
number




AMACR –1.16 –0.33 5.51 1.52 3.13 –0.40 6.50 2.11 –
BQ373258 –0.95 –0.42 100%
a 100%
a 100%
a 4.62 5.09 5.50 7.41
CV398755 – – – – – – – – –4.14
CV374350 0.03 –0.97 –0.01 0.12 –1.49 0.97 –0.62 –0.28 –4.32
AW849290 0.18 –0.20 100%
a 3.89 1.75 0.21 0.56 1.05 6.67
BE144456 0.71 –0.73 0.86 2.60 –0.36 0.56 1.31 0.70 –8.21





BF910617 0.54 –0.74 –0.25 4.56 100%
a 0.86 3.05 2.57 11.06
CV400462 –0.76 0.05 –0.11 0.85 0.01 –2.67 –0.85 –0.50 –4.11
BF365844 0.14 –0.92 2.95 2.84 1.80 0.30 –0.88 0.89 –9.28
a100% values represent expression only in tumor samples (no detectable signal in normal samples) and were converted 10-fold to calculate fold mean.
All values represent log2 of expression values, considering tumor/normal ratios.
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(see ‘Materials and methods’ section), we identiﬁed about
28% (1078 of 3834) of our transcripts as potential
ncRNA. These sequences showed a small overlap (4%)
to sequences deposited on these ncRNA databases. One
of them, CV372409 ORESTES, aligns with a sequence in
the NONCODE database and was downregulated in three
diﬀerent tumors, compared with normal tissues in our
cDNA microarray experiments. A common theme seems
to be that many ncRNA genes have a very restricted
expression. Often, they have low, or no, EST coverage,
but this does not necessarily mean that they are not
expressed and are nonfunctional (14,55).
Microarray technology has dramatically enhanced the
discovery of molecular markers for cancer. Prostate
cancer is the most prevalent cancer in Brazilian males
(http://www.inca.gov.br) as well in men wordwide
(http://www.cancer.gov), and investigators have searched
for molecular markers of the disease. The ﬁrst gene iden-
tiﬁed by cDNA microarray to be suitable for clinical prac-
tice, and to potentially improve the diagnosis of prostate
cancer was AMACR (42). AMACR was suggested as a
new molecular marker for prostate carcinoma by Xu et al.
(42) in 2000, and conﬁrmed by Jiang et al., (51). This
protein is already used clinically as an aid in distinguishing
prostate cancer from benign disease (56), and discriminat-
ing diﬀerent grades and types of prostate cancer (50).
Another potential molecular marker for prostate cancer,
identiﬁed through cDNA microarray analysis, is the poly-
comb gene, EZH2. The expression of EZH2 indicates poor
survival, and could be used as a marker for prostate
cancer progression and metastasis (57–59). Also identiﬁed
as a molecular marker is the TMPRSS2-ERG gene
fusion, which is involved in the development of prostate
cancer (60).
Increasing evidence shows a relationship between
changes in expression levels of ncRNAs and cancer
(18,61–63), emphasizing the potential role of ncRNAs in
tumorigenesis, and the potential of this type of transcript
as a tumor molecular marker (62). For example, in breast
carcinoma, BC1 is deregulated (64), and the overexpres-
sion of BC200 RNA was recently evaluated as a new
molecular marker for a poor prognosis (65). In lung
cancer, increased expression of the MALAT-1 gene indi-
cates a poor clinical outcome (66), and in hepatocellular
carcinoma, HULC ncRNA is one of the most upregulated
genes (62). In prostate cancer, there is overexpression of
PCGEM (67), and DD3
PCA3 (49) is implicated in tumor-
igenesis (68). These Endings present a strong argument for
the inclusion of noncoding transcripts into the arsenal of
markers used for molecular diagnostics, which, thus
far, has been almost exclusively populated by assays of
protein-coding transcripts (11).
We validated three diﬀerentially expressed sequences in
paired prostate samples as potential tumor markers.
Validation of the BQ373258 sequence enhanced the
value of our approach to identify molecular markers,




described as highly overexpressed in prostate cancer
tissue when compared with adjacent nonmalignant
prostatic tissue, and its expression is restricted to the pros-
tate (49). An unusually high density of stop codons has
been identiﬁed along the entire DD3
PCA3 cDNA sequence
(49,69), which, in addition to the lack of an extended open
frame and, after several years of analyzing putative pro-
teins from predicted small ORFs, has resulted in the clas-
siﬁcation of DD3
PCA3 as a polyadenylated ncRNA (69–
71). Its function is unknown, although there is speculation
that DD3
PCA3 functions to regulate gene expression or
participates in gene splicing (69). Both our cDNA micro-
array and real-time PCR show that this sequence is upre-
gulated in prostate cancer relative to normal prostate (fold
mean of 5.50 for real-time PCR and 7.41 for cDNA
microarray).
An interesting observation arises from the data of two
ORESTES, BF910617 and AW793062. ORESTES
BF910617 is aligned with an intron of the KIAA1432
gene. From the analyses performed through Oncomine
Research (http://www.oncomine.org) of the Lapointe
et al. (72) data set, we observed that, in prostate cancer
relative to normal prostate, the BF910617 ORESTES
has diametrically opposite expression compared with the
KIAA1432 gene. In the data set provided by Lapointe
et al. (72) using cDNA microarray, the KIAA1432 gene
was highly expressed in normal prostate, decreasing as the
aggressiveness of prostate cancer increased. According to
this data set, it was least expressed in metastatic prostate
cancer in the lymph node (72). Therefore, our hypothesis
is that BF910617 ORESTES may play a role in regulating
the KIAA1432 gene, inhibiting its expression in prostate
cancer when it is expressed at high levels. ORESTES
AW793062 was validated with high fold values in almost
70% of the paired samples. This sequence is located in the
ﬁrst intron of a putative isoform of the RNF217 gene.
Once again, the diﬀerential expression of AW793062 in
prostate cancer was opposite to that observed for the
RNF217 gene, with respect to primary and metastatic
prostate cancer (Oncomine Research analyses) (73).
Although the diﬀerential expression of –4.32-fold in
prostate tumor, showed by cDNA microarray experi-
ments, of the CV374350 ORESTES was not conﬁrmed
by real-time PCR, we observed that this sequence maps
to the last intron of the SGK1 gene, an inducible Ser/Thr
kinase activated via phosphoinositide 3-kinase (PI3K)
signal pathway (74,75). It is worth to note that there is
an mRNA sequence (BX649005), also mapped to the
SGK1 locus, which shows an extensive intron retention
that includes the SGK1 last intron. It has been suggested
that SGK1 may regulate androgen receptor activity,
aﬀecting androgen-mediated prostate cancer growth
through a positive-feedback mechanism (76). Oncomine
Research analysis of the SGK1 gene (73) suggests that
this gene is expressed in normal prostate and benign pros-
tate hyperplasia and its expression is fairly reduced among
primary prostate carcinoma samples but is signiﬁcantly
reduced in metastatic prostate cancer. Further analysis
of metastatic tumor samples could reveal if CV374350
expression follows the pattern of SGK1 gene expression
and if this sequence may represents an SGK1 intron reten-
tion event or may be associated with other gene-
regulation mechanism. This ORESTES was found in the
2614 Nucleic Acids Research, 2009, Vol. 37,No. 8list of cellular signal pathways related to cancer, analyzed
as described above.
The power of our data to explore uncharacterized
molecular markers was demonstrated with the large
number of diﬀerentially expressed sequences, between
tumor and normal samples from all tissues (about 28%
of the intronic and intergenic sequences mapped once on
the genome). Also, 291 of these diﬀerentially expressed
transcripts have ncRNA potential, as predicted by our
analysis. It is also very promising that at least ﬁve putative
noncoding tumor markers are upregulated in at least four
diﬀerent tumors, compared with normal tissues. On the
basis of these results, we believe in the value of our
approach to identify uncharacterized molecular markers.
Our data set contains a large number of actively tran-
scribed regions of the human genome not associated
with annotated transcripts not yet widely explored.
These may represent new genes, splice variants, NATs
or ncRNAs, which could be used as molecular markers
for other cancers.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Dr Alex Carvalho for construction of the
cDNA microarray. We thank Dra. Anamaria Camargo
for providing the prostate cancer cell lines and Dra.
Maria Mitzi Brentani and Dra. Rose Roela for
cultivating them.
FUNDING
Conselho Nacional de Desenvolvimento Cientı´ﬁco e
Tecnolo ´ gico (CNPq; 142330/2007-8 to B.P.M.); and
Fundac ¸ a ˜ o de Amparo a ` Pesquisa do Estado de
Sa ˜ o Paulo (FAPESP; 04/11774-8, 07/55791-1 to B.P.M.;
07/01549-5 to A.M.-L.). Funding for open access charge:
Conselho Nacional de Desenvolvimento Cientı´ﬁco e
Tecnolo ´ gico (CNPq).
Conﬂict of interest statement. None declared.
REFERENCES
1. Maxam,A.M. and Gilbert,W. (1977) A new method for sequencing
DNA. Proc. Natl Acad. Sci. USA, 74, 560–564.
2. Sanger,F., Nicklen,S. and Coulson,A.R. (1992) DNA sequencing
with chain-terminating inhibitors (classical article: 1977).
Biotechnology, 24, 104–108.
3. Brentani,H., Caballero,O.L., Camargo,A.A., da Silva,A.M.,
da,S.W.A. Jr, Dias,N.E., Grivet,M., Gruber,A., Guimaraes,P.E.,
Hide,W. et al. (2003) The generation and utilization of a
cancer-oriented representation of the human transcriptome by using
expressed sequence tags. Proc. Natl Acad. Sci. USA, 100,
13418–13423.
4. Birney,E., Stamatoyannopoulos,J.A., Dutta,A., Guigo,R.,
Gingeras,T.R., Margulies,E.H., Weng,Z.P., Snyder,M.,
Dermitzakis,E.T., Thurman,R.E. et al. (2007) Identiﬁcation and
analysis of functional elements in 1% of the human genome by the
ENCODE pilot project. Nature, 447, 799–816.
5. Carninci,P., Kasukawa,T., Katayama,S., Gough,J., Frith,M.C.,
Maeda,N., Oyama,R., Ravasi,T., Lenhard,B., Wells,C. et al. (2005)
The transcriptional landscape of the mammalian genome. Science,
309, 1559–1563.
6. Frith,M.C., Pheasant,M. and Mattick,J.S. (2005) The amazing
complexity of the human transcriptome. Eur. J. Hum. Genet., 13,
894–897.
7. Katayama,S., Tomaru,Y., Kasukawa,T., Waki,K., Nakanishi,M.,
Nakamura,M., Nishida,H., Yap,C.C., Suzuki,M., Kawai,J. et al.
(2005) Antisense transcription in the mammalian transcriptome.
Science, 309, 1564–1566.
8. Mattick,J.S. and Makunin,I.V. (2006) Non-coding RNA.
Hum. Mol. Genet., 15, R17–R29.
9. Mehler,M.F. and Mattick,J.S. (2006) Non-coding RNAs in the
nervous system. J. Physiol., 575, 333–341.
10. Pang,K.C., Stephen,S., Dinger,M.E., Engstrom,P.G., Lenhard,B.
and Mattick,J.S. (2007) RNAdb 2.0-an expanded database of
mammalian non-coding RNAs. Nucleic Acids Res., 35, D178–D182.
11. Reis,E.M., Nakaya,H.I., Louro,R., Canavez,F.C.,
Flatschart,A.V.F., Almeida,G.T., Egidio,C.M., Paquola,A.C.,
Machado,A.A., Festa,F. et al. (2004) Antisense intronic non-coding
RNA levels correlate to the degree of tumor diﬀerentiation in
prostate cancer. Oncogene, 23, 6684–6692.
12. Johnson,J.M., Edwards,S., Shoemaker,D. and Schadt,E.E. (2005)
Dark matter in the genome: evidence of widespread transcription
detected by microarray tiling experiments. Trends Genet., 21,
93–102.
13. Kapranov,P., Drenkow,J., Cheng,J., Long,J., Helt,G., Dike,S. and
Gingeras,T.R. (2005) Examples of the complex architecture of the
human transcriptome revealed by RACE and high-density tiling
arrays. Genome Res., 15, 987–997.
14. Weile,C., Gardner,P.P., Hedegaard,M.M. and Vinther,J. (2007)
Use of tiling array data and RNA secondary structure predictions
to identify noncoding RNA genes. BMC Genomics, 8, 244.
15. Soares,L.M.M. and Valcarcel,J. (2006) The expanding transcrip-
tome: the genome as the ‘Book of Sand’. EMBO J., 25, 923–931.
16. Seidl,C.I.M., Stricker,S.H. and Barlow,D.P. (2006) The imprinted
Air ncRNA is an atypical RNAPII transcript that evades splicing
and escapes nuclear export. EMBO J., 25, 3565–3575.
17. Goodrich,J.A. and Kugel,J.F. (2006) Non-coding-RNA regulators
of RNA polymerase II transcription. Nat. Rev. Mol. Cell Biol., 7,
612–616.
18. Nakaya,H.I., Amaral,P.P., Louro,R., Lopes,A., Fachel,A.A.,
Moreira,Y.B., El Jundi,T.A., da Silva,A.M., Reis,E.M. and
Verjovski-Almeida,S. (2007) Genome mapping and expression
analyses of human intronic noncoding RNAs reveal tissue-speciﬁc
patterns and enrichment in genes related to regulation of tran-
scription. Genome Biol., 8, R43.
19. Mattick,J.S. (2004) RNA regulation: a new genetics? Nat. Rev.
Genet., 5, 316–323.
20. Numata,K., Kanai,A., Saito,R., Kondo,S., Adachi,J.,
Wilming,L.G., Hume,D.A., Hayashizaki,Y. and Tomita,M. (2003)
Identiﬁcation of putative noncoding RNAs among the RIKEN
mouse full-length cDNA collection. Genome Res., 13, 1301–1306.
21. Kampa,D., Cheng,J., Kapranov,P., Yamanaka,M., Brubaker,S.,
Cawley,S., Drenkow,J., Piccolboni,A., Bekiranov,S., Helt,G. et al.
(2004) Novel RNAs identiﬁed from an in-depth analysis of the
transcriptome of human chromosomes 21 and 22. Genome Res., 14,
331–342.
22. Gustincich,S., Sandelin,A., Plessy,C., Katayama,S., Simone,R.,
Lazarevic,D., Hayashizaki,Y. and Carninci,P. (2006) The
complexity of the mammalian transcriptome. J. Physiol., 575,
321–332.
23. Sun,H., Skogerbo,G. and Chen,R.S. (2006) Conserved distances
between vertebrate highly conserved elements. Hum. Mol. Genet.,
15, 2911–2922.
24. Babak,T., Blencowe,B.J. and Hughes,T.R. (2005) A systematic
search for new mammalian noncoding RNAs indicates little
conserved intergenic transcription. BMC Genomics, 6, 104.
25. Washietl,S., Pedersen,J.S., Korbel,J.O., Stocsits,C., Gruber,A.R.,
Hackermuller,J., Hertel,J., Lindemeyer,M., Reiche,K., Tanzer,A.
et al. (2007) Structured RNAs in the ENCODE selected regions of
the human genome. Genome Res., 17, 852–864.
Nucleic Acids Research,2009, Vol.37, No. 8 261526. Dias,N.E., Correa,R.G., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da,S.W. Jr, Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H. et al. (2000) Shotgun sequencing of the human
transcriptome with ORF expressed sequence tags. Proc. Natl Acad.
Sci. USA, 97, 3491–3496.
27. Camargo,A.A., Samaia,H.P., Dias-Neto,E., Simao,D.F.,
Migotto,I.A., Briones,M.R., Costa,F.F., Nagai,M.A., Verjovski-
Almeida,S., Zago,M.A. et al. (2001) The contribution of 700,000
ORF sequence tags to the deﬁnition of the human transcriptome.
Proc. Natl Acad. Sci. USA, 98, 12103–12108.
28. Sironi,M., Menozzi,G., Comi,G.P., Cagliani,R., Bresolin,N. and
Pozzoli,U. (2005) Analysis of intronic conserved elements indicates
that functional complexity might represent a major source of
negative selection on non-coding sequences. Hum. Mol. Genet., 14,
2533–2546.
29. Ravasi,T., Suzuki,H., Pang,K.C., Katayama,S., Furuno,M.,
Okunishi,R., Fukuda,S., Ru,K.L., Frith,M.C., Gongora,M.M. et al.
(2006) Experimental validation of the regulated expression of large
numbers of non-coding RNAs from the mouse genome. Genome
Res., 16, 11–19.
30. de Souza,S.J., Camargo,A.A., Briones,M.R., Costa,F.F.,
Nagai,M.A., Verjovski-Almeida,S., Zago,M.A., Andrade,L.E.,
Carrer,H., El Dorry,H.F. et al. (2000) Identiﬁcation of human
chromosome 22 transcribed sequences with ORF expressed
sequence tags. Proc. Natl Acad. Sci. USA, 97, 12690–12693.
31. Fonseca,R.D., Carraro,D.M. and Brentani,H. (2006) Mining
ORESTES no-match database: can we still contribute to cancer
transcriptome? Genet. Mol. Res., 5, 24–32.
32. Sorek,R. and Safer,H.M. (2003) A novel algorithm for computa-
tional identiﬁcation of contaminated EST libraries. Nucleic Acids
Res., 31, 1067–1074.
33. Brentani,R., Carraro,D., Verjovski-Almeida,S., Reis,E., Neves,E.,
de Souza,S., Carvalho,A., Brentani,H. and Reis,L. (2005) Gene
expression arrays in cancer research: methods and applications.
Crit. Rev. Oncol. Hematol., 54, 95–105.
34. Vangelder,R.N., Vonzastrow,M.E., Yool,A., Dement,W.C.,
Barchas,J.D. and Eberwine,J.H. (1990) Ampliﬁed RNA synthesized
from limited quantities of heterogeneous cDNA. Proc. Natl Acad.
Sci. USA, 87, 1663–1667.
35. Gomes,L.I., Silva,R.L.A., Stolf,B.S., Cristo,E.B., Hirata,R.,
Soares,F.A., Reis,L.F.L., Neves,E.J. and Carvalho,A.F. (2003)
Comparative analysis of ampliﬁed and nonampliﬁed RNA for
hybridization in cDNA microarray. Anal. Biochem., 321, 244–251.
36. DeRisi,J. (2003) In Bowtell,D. and Sambrook,J (eds.), DNA
Microarrays: A Molecular Cloning Manual, Cold Spring Harbor
Laboratory Press, New York, pp. 187–193.
37. Yang,Y.H. and Speed,T. (2002) Design issues for cDNA microarray
experiments. Nat. Rev. Genet., 3, 579–588.
38. Yang,Y., Dudoit,S., Luu,P., Lin,D., Peng,V., Ngai,J. and Speed,T.
(2002) Normalization for cDNA microarray data: a robust
composite method addressing single and multiple slide systematic
variation. Nucleic Acids Res., 30, e15.
39. Kong,L., Zhang,Y., Ye,Z.Q., Liu,X.Q., Zhao,S.Q., Wei,L. and
Gao,G. (2007) CPC: assess the protein-coding potential of
transcripts using sequence features and support vector machine.
Nucleic Acids Res., 35, W345–W349.
40. Washietl,S., Hofacker,I.L. and Stadler,P.F. (2005) Fast and reliable
prediction of noncoding RNAs. Proc. Natl Acad. Sci. USA, 102,
2454–2459.
41. de Kok,J.B., Roelofs,R.W., Giesendorf,B.A., Pennings,J.L.,
Waas,E.T., Feuth,T., Swinkels,D.W. and Span,P.N. (2005)
Normalization of gene expression measurements in tumor tissues:
comparison of 13 endogenous control genes. Lab. Invest., 85,
154–159.
42. Xu,J.C., Stolk,J.A., Zhang,X.Q., Silva,S.J., Houghton,R.L.,
Matsumura,M., Vedvick,T.S., Leslie,K.B., Badaro,R. and
Reed,S.G. (2000) Identiﬁcation of diﬀerentially expressed genes in
human prostate cancer using subtraction and microarray. Cancer
Res., 60, 1677–1682.
43. Pfaﬄ,M.W. (2001) A new mathematical model for relative
quantiﬁcation in real-time RT-PCR. Nucleic Acids Res., 29, e45.
44. Pedersen,J.S., Bejerano,G., Siepel,A., Rosenbloom,K.,
Lindblad-Toh,K., Lander,E.S., Kent,J., Miller,W. and Haussler,D.
(2006) Identiﬁcation and classiﬁcation of conserved RNA secondary
structures in the human genome. Plos Comput. Biol., 2, 251–262.
45. Griﬃths-Jones,S. (2007) Annotating noncoding RNA genes.
Annu. Rev. Genomics Hum. Genet., 8, 279–298.
46. Rymarquis,L.A., Kastenmayer,J.P., Huttenhofer,A.G. and
Green,P.J. (2008) Diamonds in the rough: mRNA-like non-coding
RNAs. Trends Plant Sci., 13, 329–334.
47. Liu,C., Bai,B., Skogerbo,G., Cai,L., Deng,W., Zhang,Y., Bu,D.,
Zhao,Y. and Chen,R. (2005) NONCODE: an integrated knowledge
database of non-coding RNAs. Nucleic Acids Res., 33, D112–D115.
48. Galante,P.A.F., Vidal,D.O., de Souza,J.E., Camargo,A.A. and de
Souza,S.J. (2007) Sense-antisense pairs in mammals: functional and
evolutionary considerations. Genome Biol., 8, R40.
49. Bussemakers,M.J., van Bokhoven,A., Verhaegh,G.W., Smit,F.P.,
Karthaus,H.F., Schalken,J.A., Debruyne,F.M., Ru,N. and
Isaacs,W.B. (1999) DD3: a new prostate-speciﬁc gene, highly
overexpressed in prostate cancer. Cancer Res., 59, 5975–5979.
50. Jiang,Z., Woda,B.A., Wu,C.L. and Yang,X.M.J. (2004) Discovery
and clinical application of a novel prostate cancer marker -
alpha-Methylacyl CoA racemase (P504S). Am. J. Clin. Pathol., 122,
275–289.
51. Jiang,Z., Woda,B.A., Rock,K.L., Xu,Y.D., Savas,L., Khan,A.,
Pihan,G., Cai,F., Babcook,J.S., Rathanaswami,P. et al. (2001)
P504S - a new molecular marker for the detection of prostate
carcinoma. Am. J. Surg. Pathol., 25, 1397–1404.
52. Futreal,P., Coin,L., Marshall,M., Down,T., Hubbard,T.,
Wooster,R., Rahman,N. and Stratton,M. (2004) A census of human
cancer genes. Nat. Rev. Cancer, 4, 177–183.
53. Griﬃths-Jones,S., Moxon,S., Marshall,M., Khanna,A., Eddy,S.R.
and Bateman,A. (2005) Rfam: annotating non-coding RNAs in
complete genomes. Nucleic Acids Res., 33, D121–D124.
54. Machado-Lima,A., del Portillo,H.A. and Durham,A.M. (2008)
Computational methods in noncoding RNA research. J. Math.
Biol., 56, 15–49.
55. Pollard,K.S., Salama,S.R., Lambert,N., Lambot,M.A., Coppens,S.,
Pedersen,J.S., Katzman,S., King,B., Onodera,C., Siepel,A. et al.
(2006) An RNA gene expressed during cortical development evolved
rapidly in humans. Nature, 443, 167–172.
56. Cooper,C.S., Campbell,C. and Jhavar,S. (2007) Mechanisms of
Disease: biomarkers and molecular targets from microarray gene
expression studies in prostate cancer. Nat. Clin. Pract. Urol., 4,
677–687.
57. LaTulippe,E., Satagopan,J., Smith,A., Scher,H., Scardino,P.,
Reuter,V. and Gerald,W.L. (2002) Comprehensive gene expression
analysis of prostate cancer reveals distinct transcriptional programs
associated with metastatic disease. Cancer Res., 62, 4499–4506.
58. Varambally,S., Dhanasekaran,S.M., Zhou,M., Barrette,T.R.,
Kumar-Sinha,C., Sanda,M.G., Ghosh,D., Pienta,K.J.,
Sewalt,R.G.A.B., Otte,A.P. et al. (2002) The polycomb group
protein EZH2 is involved in progression of prostate cancer. Nature,
419, 624–629.
59. Rhodes,D.R., Sanda,M.G., Otte,A.P., Chinnaiyan,A.M. and
Rubin,M.A. (2003) Multiplex biomarker approach for determining
risk of prostate-speciﬁc antigen-deﬁned recurrence of prostate
cancer. J. Natl Cancer Inst., 95, 661–668.
60. Tomlins,S.A., Rhodes,D.R., Perner,S., Dhanasekaran,S.M.,
Mehra,R., Sun,X.W., Varambally,S., Cao,X.H., Tchinda,J.,
Kuefer,R. et al. (2005) Recurrent fusion of TMPRSS2 and ETS
transcription factor genes in prostate cancer. Science, 310, 644–648.
61. Reis,E.M., Ojopi,E.P.B., Alberto,F.L., Rahal,P., Tsukumo,F.,
Mancini,U.M., Guimaraes,G.S., Thompson,G.M.A., Camacho,C.,
Miracca,E. et al. (2005) Large-scale transcriptome analyses reveal
new genetic marker candidates of head, neck, and thyroid cancer.
Cancer Res., 65, 1693–1699.
62. Panzitt,K., Tschernatsch,M.M.O., Guelly,C., Moustafa,T.,
Stradner,M., Strohmaier,H.M., Buck,C.R., Denk,H., Schroeder,R.,
Trauner,M. et al. (2007) Characterization of HULC, a novel gene
with striking up-regulation in hepatocellular carcinoma, as non-
coding RNA. Gastroenterology, 132, 330–342.
63. Brito,G.C., Fachel,A.A., Vettore,A.L., Vignal,G.M., Gimba,E.R.,
Campos,F.S., Barcinski,M.A., Verjovski-Almeida,S. and Reis,E.M.
(2008) Identiﬁcation of protein-coding and intronic noncoding
RNAs down-regulated in clear cell renal carcinoma. Mol. Carcinog.,
47, 757–767.
2616 Nucleic Acids Research, 2009, Vol. 37,No. 864. Chen,W., Bocker,W., Brosius,J. and Tiedge,H. (1997) Expression of
neural BC200 RNA in human tumours. J. Pathol., 183, 345–351.
65. Iacoangeli,A., Lin,Y., Morley,E.J., Muslimov,I.A., Bianchi,R.,
Reilly,J., Weedon,J., Diallo,R., Bocker,W. and Tiedge,H. (2004)
BC200 RNA in invasive and preinvasive breast cancer.
Carcinogenesis, 25, 2125–2133.
66. Ji,P., Diederichs,S., Wang,W.B., Boing,S., Metzger,R.,
Schneider,P.M., Tidow,N., Brandt,B., Buerger,H., Bulk,E. et al.
(2003) MALAT-1, a novel noncoding RNA, and thymosin beta 4
predict metastasis and survival in early-stage non-small cell lung
cancer. Oncogene, 22, 8031–8041.
67. Srikantan,V., Zou,Z.Q., Petrovics,G., Xu,L., Augustus,M.,
Davis,L., Livezey,J.K., Connell,T., Sesterhenn,I.A., Yoshino,K.
et al. (2000) PCGEM1, a prostate-speciﬁc gene, is overexpressed in
prostate cancer. Proc. Natl Acad. Sci. USA, 97, 12216–12221.
68. Petrovics,G., Zhang,W., Makarem,M., Street,J.P., Connelly,R.,
Sun,L., Sesterhenn,I.A., Srikantan,V., Moul,J.W. and Srivastava,S.
(2004) Elevated expression of PCGEM1, a prostate-speciﬁc gene
with cell growth-promoting function, is associated with high-risk
prostate cancer patients. Oncogene, 23, 605–611.
69. Schalken,J.A., Hessels,D. and Verhaegh,G. (2003) New targets for
therapy in prostate cancer: Diﬀerential display code 3 (DD3(PCA3))
a highly prostate cancer-speciﬁc gene. Urology, 62, 34–43.
70. Hessels,D., Gunnewiek,J.M.T.K., van Oort,I., Karthaus,H.F.M.,
van Leenders,G.J.L., van Balken,B., Kiemeney,L.A., Witjes,J.A.
and Schalken,J.A. (2003) DD3(PCA3)-based molecular urine
analysis for the diagnosis of prostate cancer. Eur. Urol., 44, 8–15.
71. Tinzl,M., Marberger,M., Horvath,S. and Chypre,C. (2004)
DD3(PCA3) RNA analysis in urine - a new perspective for
detecting prostate cancer. Eur. Urol., 46, 182–187.
72. Lapointe,J., Li,C., Higgins,J.P., van de Rijn,M., Bair,E.,
Montgomery,K., Ferrari,M., Egevad,L., Rayford,W.,
Bergerheim,U. et al. (2004) Gene expression proﬁling identiﬁes
clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci.
USA, 101, 811–816.
73. Dhanasekaran,S.M., Barrette,T.R., Ghosh,D., Shah,R.,
Varambally,S., Kurachi,K., Pienta,K.J., Rubin,M.A. and
Chinnaiyan,A.M. (2001) Delineation of prognostic biomarkers in
prostate cancer. Nature, 412, 822–826.
74. Kobayashi,T. and Cohen,P. (1999) Activation of serum- and
glucocorticoid-regulated protein kinase by agonists that
activate phosphatidylinositide 3-kinase is mediated by
3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2.
Biochem. J., 339 (Pt 2), 319–328.
75. Park,J., Leong,M., Buse,P., Maiyar,A., Firestone,G. and
Hemmings,B. (1999) Serum and glucocorticoid-inducible kinase
(SGK) is a target of the PI 3-kinase-stimulated signaling pathway.
EMBO J., 18, 3024–3033.
76. Shanmugam,I., Cheng,G., Terranova,P., Thrasher,J., Thomas,C.
and Li,B. (2007) Serum/glucocorticoid-induced protein kinase-1
facilitates androgen receptor-dependent cell survival. Cell Death
Diﬀer., 14, 2085–2094.
Nucleic Acids Research,2009, Vol.37, No. 8 2617